Fauci's researchers find better antibody response from natural immunity than Moderna vaccine

A month before America's top infectious disease bureaucrat conceded that mRNA vaccines offer only short-lived protection against COVID-19, Anthony Fauci's researchers at the National Institute of Allergy and Infectious Disease (NIAID) offered a possible explanation why.

These vaccines target COVID's spike protein, whereas natural immunity recognizes the whole of the virus, including the nucleocapsid protein that envelops the RNA core.

Among those infected during the "blinded phase" of Moderna's 30,000-adult vaccine trial, only 40% of those given the vaccine developed anti-nucleocapsid antibodies. The figure was more than twice as high (93%) for those given the placebo.